Program
vunakizumab
Also written as “SHR-1314”, “SHR-1314 injection” and “SHR-1314 Injection”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Non-Radiographic Axial Spondyloarthritis · Graves Ophthalmopathy · Spondylitis, Ankylosing, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 174 open or running | phase 4since Jan 7, 2025 | Sep 20, 2016 | Mar 2027phase 4 · NCT06779097 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Sep 20, 2016.
- Jan 22, 2018Phase 2 study in Moderate-to-severe Chronic Plaque PsoriasisNCT03463187 · 211 enrolled · United States, Australia, China
- Sep 6, 20182 phase 1 studiesNCT03710681, NCT03704428
- Sep 27, 2019Phase 2 study in Plaque PsoriasisNCT04121143 · 120 enrolled · China
- Mar 24, 2020Phase 1 study in PharmacokineticNCT04326881 · 30 enrolled
- Aug 23, 2020Phase 1 study in BioequivalenceNCT04527484 · 130 enrolled
- Apr 7, 20212 phase 3 studiesNCT04840485, NCT04839016
- Jun 7, 2021Phase 2 study in Lupus NephritisNCT04924296 · 60 enrolled
- Sep 15, 2021Phase 2 study in Arthritis, PsoriaticNCT05055934 · 112 enrolled · China
- May 23, 2022Phase 2 study in Active Moderate to Severe Graves' OrbitopathyNCT05394857 · 7 enrolled · China
- Dec 4, 2023Phase 1 study in Moderate-to-Severe Plaque PsoriasisNCT06182384 · 46 enrolled · China
- Oct 10, 2024Phase 3 study in Arthritis, PsoriaticNCT06640257 · 208 enrolled · China
- Jan 7, 2025Phase 4 study in Moderate to Severe Plaque PsoriasisNCT06779097 · 1,564 planned · China
- Feb 11, 2025Phase 3 study in Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque PsoriasisNCT06833307 · 90 planned · China
- Mar 2, 2025Phase 3 study in Active Non-radiographic Axial SpondyloarthritisNCT06860750 · 380 planned · China
Ahead
- Mar 2027Primary completion: phase 4 study in Moderate to Severe Plaque PsoriasisNCT06779097
- Feb 2028Primary completion: phase 3 study in Active Non-radiographic Axial SpondyloarthritisNCT06860750
TargetBeta
“Interleukin 17A inhibitor”ChEMBL 37, by rule
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 128 |
| ixekizumabrule | Eli Lilly | phase 4 | 38 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06860750Active Non-radiographic Axial Spondyloarthritis · China | 3 | Recruiting | Feb 2028 | 380 |
| NCT06833307Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis · China | 3 | Not yet recruiting | Jul 2026 | 90 |
| NCT06779097Moderate to Severe Plaque Psoriasis · China | 4 | Not yet recruiting | Mar 2027 | 1,564 |
| NCT06640257Arthritis, Psoriatic · China | 3 | Active, not recruiting | Jun 5, 2026 | 208 |
| NCT06182384Moderate-to-Severe Plaque Psoriasis · China | 1 | Completed | May 13, 2024 | 46 |
| NCT05394857Active Moderate to Severe Graves' Orbitopathy · China | 2 | Terminated | Aug 22, 2023 | 7 |
| NCT05055934Arthritis, Psoriatic · China | 2 | Completed | Jun 5, 2024 | 112 |
| NCT04924296Lupus Nephritis | 2 | UNKNOWN | Dec 25, 2021 | 60 |
| NCT04839016Moderate-to-Severe Plaque Psoriasis | 3 | UNKNOWN | Aug 30, 2023 | 660 |
| NCT04840485Spondylitis, Ankylosing · China | 3 | Completed | Nov 3, 2023 | 548 |
| NCT04527484Bioequivalence | 1 | UNKNOWN | Jan 10, 2021 | 130 |
| NCT04326881Pharmacokinetic | 1 | UNKNOWN | Jul 7, 2020 | 30 |
| NCT04121143Plaque Psoriasis · China | 2 | Suspended | Jun 30, 2020 | 120 |
| NCT03704428Axial Spondyloarthritis · China | 1 | Completed | Jan 14, 2020 | 45 |
| NCT03710681Moderate-to-severe Plaque Psoriasis · China | 1 | UNKNOWN | Apr 21, 2019 | 16 |
| NCT03463187Moderate-to-severe Chronic Plaque Psoriasis · United States, Australia, China | 2 | Completed | Aug 31, 2020 | 211 |
| NCT02934412Psoriasis · Australia | 1 | Completed | Jun 30, 2017 | 40 |
How it is read
Names in the registry
- “SHR-1314”, 14 entries
- “SHR-1314 injection”, 2 entries
- “SHR-1314 Injection”, 1 entry
- “Vunakizumab (IL-17A inhibitor)”, 1 entry
- “IL-17A Antagonist”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 8 studies
- Arthritis, Psoriatic, 2 studies
- Non-Radiographic Axial Spondyloarthritis, 1 study
- Graves Ophthalmopathy, 1 study
- Spondylitis, Ankylosing, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.